TAU lab identifies effective antibodies from recovered Coronavirus patients

Written on |

Antibody-based therapies can be used to protect at-risk populations, including medical workers, from the virus

The race to develop effective antibody-based treatments for COVID-19 is advancing at a rapid pace. Now, a Tel Aviv University laboratory reports it has successfully isolated two antibodies that would neutralize the virus’s ability to infect human cells. The two suitable antibodies were identified in patients recovering from COVID-19, according to Dr. Natalia Freund who heads the Laboratory for Human Antibody Responses at TAU’s Sackler Faculty of Medicine. “The use of antibodies bears significant potential as a treatment for high-risk coronavirus patients and as a preventative measure for at-risk groups, like medical workers and essential employees, exposed to the virus,” she explains.

The weak link in the virus chain

In the long run, identifying effective antibodies against virus neutralization could also accelerate the development of vaccines for the disease. Dr. Freund, who together with her team pinpointed the antibodies in blood samples of recovering patients, say that antibodies would be key to identifying the elusive vulnerable Achilles’ heel of the virus, which scientists have identified as somewhere along its spike protein, the structure that allows it to break into a cell. Dr. Freund is collaborating with researchers in San Diego to test the efficacy of antibody treatments in animal models against a live active virus. The trials are scheduled to take place this month. Only if and when the trials are successful in animal models will the option of clinical trials be considered. “If we complete the trials successfully and are able to eventually develop this treatment, it could be used to help treat at-risk patients such as the elderly or immunocompromised patients. Antibodies can also remain active in the blood for many weeks – up to two months – so injecting antibodies can afford medical teams and other at-risk groups temporary protection against the virus.”

Related posts

As Pandemic Persists, TAU Forges Ahead with COVID-19 Research on All Fronts

30 December 2021

Seaweed – A Promising Defense Against Covid-19

16 December 2021

TAU Experts on Omicron: “Don’t Panic”

7 December 2021

TAU Researchers Identify COVID Proteins that Cause Strokes and Heart Attacks

8 November 2021

From Law and Education to Nursing

3 November 2021

COVID-19 Immunity Varies Among Genders and Age Groups

25 July 2021

New study found differences between women and men in the level of COVID-19 antibodies

16 July 2021

How Will We Brave the Post-COVID Era?

1 June 2021

British Variant 45% More Contagious than Original Virus

29 April 2021

COVID-19 Vaccinations at TAU

25 March 2021

Covid-19 Vaccination of Nursing Mothers May Protect Babies

25 March 2021

Academic First Responders

14 January 2021

TAU Study Proves that Light Can Kill Coronavirus

15 December 2020

COVID-19 Takes TAU’s Legal Clinics into High Gear

7 December 2020

Study: Women Suffer More from COVID-related Orofacial Pain

13 November 2020

TAU Researchers Discover Antibody Combo that Fights COVID-19

13 October 2020

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: office@aftau.asn.au

New South Wales

P.O. Box 4044, Maroubra South,
NSW 2035
Phone: +61 418 465 556
Email: davidsolomon@aftau.org.au

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: clivedonner@thelinqgroup.com